Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough

NCT04030026 is registered in ClinicalTrials.gov with Trevi Therapeutics as lead sponsor.

NCT NCT04030026
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04030026 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough
Lead sponsor
Trevi Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 29, 2019
Completion date
May 27, 2022
Enrollment
42 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis